Cisplatin-induced peripheral neuropathic pain is a common adverse effect of chemotherapy. The present study evaluated the effects of 2’-chloro-6-methylflavone (2’-Cl-6MF) at recombinant α1β2γ2L, α2β1-3γ2L, and α3β1-3γ2L GABA-A receptor subtypes expressed in Xenopus oocytes and subsequently evaluated its effectiveness in cisplatin-induced neuropathic pain. The results showed that 2’-Cl-6MF potentiated GABA-elicited currents at α2β2/3γ2L and α3β2/3γ2L GABA-A receptor subtypes. The potentiation was blocked by the co-application of flumazenil (a benzodiazepine (BDZs) site antagonist). In behavioral studies, mechanical allodynia was induced by intraplantar injection of cisplatin (40 μg/paw) in Sprague Dawley rats, and behavioral assessments were made 24 h after injection. 2’-Cl-6MF (1, 10, 30, and 100 mg/kg, i.p.), was administered 1 h before behavioral evaluation. Administration of 2’-Cl-6MF (30 and 100 mg/kg, i.p) significantly enhanced the paw withdrawal threshold and decreased mechanical allodynia. The standard drugs, gabapentin (GBP) at the dose of 70 mg/kg, and HZ 166 (16 mg/kg), i.p. also significantly enhanced the paw withdrawal threshold in mechanical allodynia. Pretreatment with pentylenetetrazole (PTZ) (15 mg/kg, i.p.) and flumazenil reversed the antinociceptive effect of 2’-Cl-6MF in mechanical allodynia indicating GABAergic mechanisms. Moreover, the binding mechanism of 2’-Cl-6MF was rationalized by in silico modeling tools. The 3D-coordinates of α2β2γ2L and α2β3γ2L were generated after homology modeling of the α2 subtype and 2’-Cl-6MF was at predicted binding sites of the developed models. The α2 model was compared with the α1 and α3 subunits via structural and sequence alignment. Molecular docking depicted that the compound binds efficiently at the neuromodulator binding site of the receptors. The findings of this study revealed that 2’-Cl-6MF ameliorated the manifestations of cisplatin-induced neuropathic pain in rats. Furthermore, we also conclude that GABAergic mechanisms may contribute to the antinociceptive effect of 2’-Cl-6MF. The molecular docking studies also confirm the involvement of the BDZs site of GABA-A receptors. It was observed that Ile230 of α2 stabilize the chlorophenyl ring of 2’-Cl-6MF through hydrophobic interactions, which is replaced by Val203 in α1 subunit. However, the smaller side chain of Val203 does not provide hydrophobic interaction to the compound due to high conformational flexibility of α1 subunit.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Akbar S, Subhan F, Karim N, Aman U, Ullah S, Shahid M, Ahmad N, Fawad K, Sewell RDE (2017) Characterization of 6-methoxyflavanone as a novel anxiolytic agent: a behavioral and pharmacokinetic approach. Eur J Pharmacol 801:19–27
Barnard EA (2001) The molecular architecture of GABA-A receptors. In: pharmacology of GABA and Glycine neurotransmission. In: Möhler HE (ed) The molecular architecture of GABA-A receptors. Springer, Berlin, p 2001
Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C (2008) Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136:380–387
Cheng J-K, Chiou L-C (2006) Mechanisms of the Antinociceptive action of gabapentin. J Pharmacol Sci 100:471–486
Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A et al (2003) Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature. 424:938–942
Deng L, Guindon J, Vemuri VK, Thakur GA, White FA, Makriyannis A et al (2012) The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB(2) receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Mol Pain 8:71
Deuis JR, Lim YL, Rodrigues de Sousa S, Lewis RJ, Alewood PF, Cabot PJ et al (2014) Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin. Neuro-oncology 16:1324–1332
Di Lio A, Benke D, Besson M, Desmeules J, Daali Y, Wang ZJ et al (2011) HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology. 60:626–632
Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, Stewart DJ (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10:795–803
Hanrahan JR, Chebib M, Johnston GA (2015) Interactions of flavonoids with ionotropic GABA receptors. Adv Pharmacol 72:189–200
Harvey RJ, Depner UB, Wassle H, Ahmadi S, Heindl C, Reinold H et al (2004) GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science. 304:884–887
Jensen TS, Madsen CS, Finnerup NB (2009) Pharmacology and treatment of neuropathic pains. Curr Opin Neurol 22:467–474
Karim N, Gavande N, Wellendorph P, Johnston GA, Hanrahan JR, Chebib M (2011) 3-Hydroxy-2′-methoxy-6-methylflavone: a potent anxiolytic with a unique selectivity profile at GABA(A) receptor subtypes. Biochem Pharmacol 82:1971–1983
Karim N, Curmi J, Gavande N, Johnston GA, Hanrahan JR, Tierney ML et al (2012) 2′-Methoxy-6-methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABA(A) receptors. Br J Pharmacol 165:880–896
Knabl J, Witschi R, Hosl K, Reinold H, Zeilhofer UB, Ahmadi S et al (2008) Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature. 451:330–334
Knabl J, Zeilhofer UB, Crestani F, Rudolph U, Zeilhofer HU (2009) Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. Pain. 141:233–238
Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, Krarup C (1993) Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain. 116(Pt 5):1017–1041
Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A (2013) Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther 12:1537–1544
Liu JJ, Kim Y, Yan F, Ding Q, Ip V, Jong NN, Mercer JFB, McKeage MJ (2013) Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. Biochem Pharmacol 85:207–215
Miri A, Sharifi-Rad J, Tabrizian K, Nasiri AA (2015) Antinociceptive and anti-inflammatory activities of Teucrium persicum Boiss. Extract Mice Sci 2015:972827
Olsen RW, Sieghart W (2008) International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 60:243–260
Park HJ (2014) Chemotherapy induced peripheral neuropathic pain. Korean J Anesthesiol 67:4–7
Park HJ, Stokes JA, Pirie E, Skahen J, Shtaerman Y, Yaksh TL (2013) Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept. Anesth Analg 116:224–231
Prieto-Martínez FD, López-López E, Juárez-Mercado KE, Medina-Franco JL (2019) Computational drug design methods—current and future perspectives. In silico drug design: Elsevier. p. 19–44
Quintão NLM, Santin JR, Stoeberl LC, Corrêa TP, Melato J, Costa R (2019) Pharmacological treatment of chemotherapy-induced neuropathic pain: PPARγ agonists as a promising tool. Front Neurosci 13
Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG (2008) Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 327:584–591
Ren L, Wang F, Xu Z, Chan WM, Zhao C, Xue H (2010) GABAA receptor subtype selectivity underlying anxiolytic effect of 6-hydroxyflavone. Biochem Pharmacol 79:1337–1344
Roelofs RI, Hrushesky W, Rogin J, Rosenberg L (1984) Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 34:934–938
Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM et al (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 401:796–800
Sang CS, Hayes KS (2006) Anticonvulsant medications in neuropathic pain. In: McMahon SB, K. M, (eds) Wall and Melzack's Textbook of Pain. Elsevier
Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, le-Lindqwister N, Gilman PB, Shapiro CL, Alliance for Clinical Trials in Oncology (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. J Am Med Assoc 309:1359–1367
Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G et al (2013) Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A 110:11199–11204
Ta LE, Low PA, Windebank AJ (2009) Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 5:9
Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC (1984) Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 54:1269–1275
van der Burg ME, de Wit R, van Putten WL, Logmans A, Kruit WH, Stoter G et al (2002) Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 86:19–25
Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M, Kerestes ZL (1990) A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61:608–611
Zeilhofer HU (2008) Loss of glycinergic and GABAergic inhibition in chronic pain--contributions of inflammation and microglia. Int Immunopharmacol 8:182–187
Dr. Nasiara Karim acknowledges funding (National research program for universities; NRPU 20-3425) from the Higher Education Commission of Pakistan for the completion of this research work. The funding body did not contribute to the design or any other part of the research work. We also acknowledge Professor Dr. Mary Collins, faculty of Pharmacy, the University of Sydney for providing technical assistance in oocytes experiments.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Karim, N., Khan, I., Abdelhalim, A. et al. Involvement of selective GABA-A receptor subtypes in amelioration of cisplatin-induced neuropathic pain by 2’-chloro-6-methyl flavone (2’-Cl-6MF). Naunyn-Schmiedeberg's Arch Pharmacol (2020). https://doi.org/10.1007/s00210-020-02021-x
- Chemotherapy-induced neuropathic pain
- Mechanical allodynia